Sensory profiles are heterogeneous in neuropathic pain disorders, and subgroups of
patients respond differently to treatment. To further explore this, patients in the COMBO-DN
study were prospectively assessed by the Neuropathic Pain Symptom Inventory (NPSI) at
baseline, after initial 8-week therapy with either duloxetine or pregabalin, and after
subsequent 8-week combination/high-dose therapy. Exploratory post hoc cluster analyses
were performed to identify and characterize potential subgroups through their scores in the …